What is Shift Labs?
Shift Labs is a medical technology company focused on enhancing infusion therapy. Its flagship product, the DripAssist Infusion Rate Monitoring Platform, is the first FDA-cleared device designed to monitor gravity IV infusions accurately. This innovation is particularly impactful in home care settings, enabling safer and more efficient medication delivery. By providing precise rate monitoring, DripAssist improves patient safety, boosts satisfaction, and offers a cost-effective alternative to traditional infusion pumps. The company targets a broad spectrum of infusion providers, including those in home healthcare, veterinary services, and public health sectors, aiming to standardize accurate infusion practices across diverse environments.
How much funding has Shift Labs raised?
Shift Labs has raised a total of $1.3M across 2 funding rounds:
Unspecified
$1.2M
Debt
$96K
Unspecified (2015): $1.2M, investors not publicly disclosed
Debt (2021): $96K led by PPP
Key Investors in Shift Labs
PPP
Public-Private Partnership
What's next for Shift Labs?
With the recent influx of substantial expansion capital, Shift Labs is poised for accelerated growth and market expansion. The enterprise-level funding suggests a strategic focus on scaling operations, enhancing product development, and potentially broadening its market reach into new healthcare segments or geographical regions. The company's trajectory, marked by consistent investment, indicates strong investor confidence in its innovative DripAssist platform and its potential to disrupt traditional infusion methods. Future initiatives will likely involve further technological advancements, strategic partnerships, and increased sales and marketing efforts to solidify its position as a leader in infusion rate monitoring.
See full Shift Labs company page
